INTELLIGENT BIO SOLUTIONS INC. (INBS)
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Intelligent Bio Solutions Inc.
| Form | Description | Links | |
|---|---|---|---|
| PRE 14A | |||
| 10-K/A | |||
| 8-K | |||
| EFFECT | |||
| 424B3 | |||
| S-3 | |||
| D | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 10-K | |||
| 13G/A | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 13G | |||
| 8-K |
1-25 of 465 filings
Recent SEC filings with analysis
- 424B3Intelligent Bio Solutions (INBS) filed a 424B3 prospectus registering 6,211,809 shares for resale by selling stockholders, including shares issuable upon…
- S-3Intelligent Bio Solutions (INBS) filed an S-3 registering 6,211,809 shares of common stock for resale by selling stockholders, led by Alyeska Master Fund, L.P.